Mankind Pharma Q2 FY26 Earnings Results

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.

 

Q2 FY26 Earnings Results

• Revenue from Operations: ₹3,697.16 crore, up 20.77% YoY and 3.55% QoQ.

• EBITDA: ₹924 crore, with an EBITDA margin of 25.0%, representing an 8.7% YoY increase.

• Profit After Tax (PAT): ₹520 crore, down 21.5% YoY but up 16.7% QoQ.

• PAT margin: Approximately 14.1%.

• Domestic revenue rose 14.5% YoY to ₹3,184 crore.

• Exports surged 82.6% YoY, boosted by integration of Bharat Serums and Vaccines (BSV).

• Chronic segment saw strong performance with 1.3x growth in Cardiac and 1.2x in Anti-Diabetics.

• Consumer healthcare revenue declined 3% YoY, affected by supply chain issues and uneven monsoon.

 

Management Commentary & Strategic Decisions

• Vice Chairman & MD Rajeev Juneja highlighted strong growth led by chronic segment and BSV integration, with short-term challenges in consumer healthcare due to GST disruptions and monsoon impact.

• Focus on synergy realization from BSV acquisition to enhance revenue and cost efficiencies.

• Management emphasized sustained volume growth, market share gains, and a robust product pipeline including vaccines and biologics.

• Confident on long-term growth despite near-term margin pressures and external challenges.

 

 

Q1 FY26 Earnings Results

• Revenue from Operations: ₹3,570.35 crore, up 24.4% YoY from ₹2,867.85 crore in Q1 FY25.

• Profit After Tax (PAT): ₹445 crore, down 18% YoY.

• EBITDA: ₹850 crore, with margin improving marginally to 23.8%.

• Strong growth in chronic and export businesses; consumer segment also showed growth.

• Increased costs in employee expenses, R&D, and raw materials impacted margins.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.